3.39

2.42% 0.08

After Hours: 3.37 -0.02 -0.59%

Abcellera Biologics Inc (ABCL)

Overview News Price History Option Chain Financials Why ABCL Down? Discussions Forecast

Abcellera Biologics Inc stock is traded at $3.39, with a volume of 1.66M. It is up +2.42% in the last 24 hours and up +6.27% over the past month. AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications. ABCL635, ABCL386, ABCL575, and ABCL635.

Previous Close:

$3.31

Open:

$3.39

24h Volume:

1.66M

Relative Volume:

0.42

Market Cap:

$1.03B

Revenue:

$75.13M

Net Income/Loss:

$-146.41M

P/E Ratio:

-6.9127

EPS:

-0.4904

Net Cash Flow:

$-174.43M

1W Performance:

-3.69%

1M Performance:

+6.27%

6M Performance:

-27.10%

1Y Performance:

+33.99%

1-Day Range:

$3.36

$3.525

1-Week Range:

$3.26

$3.59

52-Week Range:

$1.8906

$6.515

Abcellera Biologics Inc Stock (ABCL) Company Profile

Name

Abcellera Biologics Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

(604) 559-9005

Address

150 W 4TH AVENUE, VANCOUVER

Employee

562

Twitter

Next Earnings Date

2024-11-18

Latest SEC Filings

ABCL's Discussions on Twitter

Compare ABCL vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABCL Abcellera Biologics Inc	3.39	1.00B	75.13M	-146.41M	-174.43M	-0.4904
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-07-25	Downgrade	Leerink Partners	Outperform → Market Perform
Jul-07-25	Resumed	Leerink Partners	Outperform
Aug-20-24	Downgrade	The Benchmark Company	Buy → Hold
Feb-22-24	Upgrade	The Benchmark Company	Hold → Buy
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight
Nov-06-23	Downgrade	The Benchmark Company	Buy → Hold
Oct-13-23	Resumed	Piper Sandler	Overweight
Feb-28-23	Initiated	Cowen	Outperform
Dec-15-22	Initiated	Goldman	Buy
Nov-16-22	Initiated	Truist	Buy
Dec-21-21	Initiated	The Benchmark Company	Buy
Nov-19-21	Initiated	Piper Sandler	Overweight
Jan-05-21	Initiated	BMO Capital Markets	Outperform
Jan-05-21	Initiated	Berenberg	Buy
Jan-05-21	Initiated	Credit Suisse	Outperform
Jan-05-21	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	Stifel	Buy

View All

Abcellera Biologics Inc Stock (ABCL) Latest News

Mar 25, 2026

Sentiment Watch: What hedge funds are buying AbCellera Biologics IncEarnings Overview Summary & Weekly Stock Breakout Alerts - baoquankhu1.vn

Mar 25, 2026

Mar 23, 2026

What sparked AbCellera Biologics to soar over 9% after hours - MSN

Mar 23, 2026

Mar 22, 2026

AbCellera Biologics (ABCL) Goldman Sachs 45th Annual Global Healthcare Conference summary - Quartr

Mar 22, 2026